To determine the ablation centration, efficacy, predictability, and safety of CustomVue LASIK using the VISX S4 excimer laser for the treatment of myopia and myopic astigmatism.METHODS
A retrospective review of 20 myopic eyes of 12 patients treated with LASIK CustomVue VISX S4 was conducted. Corneal topography was used to determine ablation centration. Primary outcome variables including manifest refraction, best spectacle-corrected visual acuity (BSCVA), uncorrected visual acuity (UCVA), and complications were evaluated at 3 months postoperatively.RESULTS
Mean decentration (from ablation zone to entrance pupil) was 0.23±0.08 mm at 3 months postoperatively. No eyes were decentered >0.5 mm. Preoperatively, the mean spherical equivalent refraction was −4.81±1.39 diopters (D) (range: −6.75 to −2.25 D). At 3 months postoperatively, mean spherical equivalent refraction was −0.63±0.25 D (range: −2.00 to 0.25 D). Nineteen (95%) of 20 eyes had UCVA of 20/40 and 16 (80%) of 20 eyes had UCVA of 20/20 at 3 months postoperatively. Fourteen (70%) eyes were within ±0.50 D and 18 (90%) eyes were within ±1.00 D of emmetropia. No eye lost >1 line of BSCVA.CONCLUSIONS
Wavefront-guided LASIK using the CustomVue VISX S4 for myopic eyes results in minimal decentration ablation and effective, predictable, and safe visual outcomes.